Ophthalmology. Retina最新文献

{"title":"Intravitreal Nematode","authors":"Vasco Lobo MD , Paulo Rosa MD , Inês Leal MD, PhD","doi":"10.1016/j.oret.2025.02.021","DOIUrl":"10.1016/j.oret.2025.02.021","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 10","pages":"Page e99"},"PeriodicalIF":5.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Effects of Anti-VEGF Therapy versus Panretinal Photocoagulation on Retinal Vessel Caliber in Eyes with Proliferative Diabetic Retinopathy","authors":"Steven Shen MD ,&nbsp;Kristin Josic PhD ,&nbsp;Jeong W. Pak PhD ,&nbsp;Stacy M. Meuer BS ,&nbsp;Michele Melia ScM ,&nbsp;Amitha Domalpally MD, PhD ,&nbsp;Jennifer K. Sun MD, MPH ,&nbsp;Barbara Blodi MD ,&nbsp;DRCR Retina Network","doi":"10.1016/j.oret.2025.03.027","DOIUrl":"10.1016/j.oret.2025.03.027","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the long-term effects of ranibizumab<span><span><span> compared with panretinal photocoagulation (PRP) on retinal </span>vasculature in eyes with </span>proliferative diabetic retinopathy (PDR).</span></div></div><div><h3>Design</h3><div>Post hoc analysis<span> of DRCR Retina Network Protocol S randomized clinical trial.</span></div></div><div><h3>Participants</h3><div>Adults with type 1 or 2 diabetes and PDR in at least 1 eye.</div></div><div><h3>Methods</h3><div><span><span>Integrative Vessel Analysis software was used to measure central retinal arteriolar equivalent (CRAE) and central retinal venular equivalent (CRVE) of vessels at 1 disc diameter from the optic nerve edge on fundus photographs at baseline, 2 and 5 years for study eyes randomized to </span>ranibizumab or PRP treatment for PDR. Changes in CRAE and CRVE were analyzed using mixed </span>linear regression models with multivariable adjustments.</div></div><div><h3>Main Outcome Measures</h3><div>Mean change in CRAE and CRVE from baseline to 2 and 5 years.</div></div><div><h3>Results</h3><div><span>Data from 107 eyes (90 participants) in the ranibizumab (n = 48) and PRP group (n = 59) were analyzed. For the ranibizumab versus PRP groups, CRAE decreased by a mean of 2 versus 12 μm at 2 years (mean difference, 10 μm; 95% confidence interval [CI], 4-16; </span><em>P</em> = 0.003); and 9 versus 13 μm at 5 years (mean difference, 4 μm; 95% CI, −2 to 10; <em>P</em> = 0.22). Central retinal venular equivalent decreased by 14 versus 19 μm at 2 years (mean difference, 4 μm; 95% CI, −3 to 11; <em>P</em> = 0.26) and 18 versus 28 μm at 5 years (mean difference, 11 μm; 95% CI, 3-19; <em>P</em> = 0.01).</div></div><div><h3>Conclusions</h3><div>In patients with PDR, CRAE and CRVE decreased in both the ranibizumab and PRP groups at 5 years, but the rates of change before and after 2 years may be different. In this subset of eyes from Protocol S, the greater reduction in CRAE in the PRP group was statistically significant at 2 years but not at 5 years.</div><div>For CRVE, the PRP group decreased more than the ranibizumab group, but the difference was statistically significant at 5 but not 2 years. Future research may investigate the underlying causes for retinal arteriolar and venular narrowing after treatment for PDR, and the possibility of an anatomic correlation with visual field loss.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 10","pages":"Pages 964-971"},"PeriodicalIF":5.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Clinical Spectrum of Polypoidal Choroidal Vasculopathy in White Patients","authors":"Marc J. Sirks MD ,&nbsp;Elon H.C. van Dijk MD, PhD ,&nbsp;Husein Ghalayini MD ,&nbsp;Somayeh Bazdar MD ,&nbsp;Weifeng Yu MD ,&nbsp;Suzanne Yzer MD, PhD ,&nbsp;José P. Martinez Ciriano MD ,&nbsp;Reinier O. Schlingemann MD, PhD ,&nbsp;Roselie M.H. Diederen MD, PhD ,&nbsp;Camiel J.F. Boon MD, PhD","doi":"10.1016/j.oret.2025.04.019","DOIUrl":"10.1016/j.oret.2025.04.019","url":null,"abstract":"<div><h3>Purpose</h3><div>To describe clinical characteristics of polypoidal choroidal vasculopathy (PCV) in a large White cohort.</div></div><div><h3>Design</h3><div>Multicenter retrospective cohort study in 3 tertiary referral centers in the Netherlands.</div></div><div><h3>Subjects</h3><div>White patients with an indocyanine green angiography–confirmed diagnosis of PCV in 1 or both eyes.</div></div><div><h3>Methods</h3><div>The medical charts and multimodal imaging (MMI) of the included patients were assessed retrospectively by 2 independent assessors. Any discrepancies between graders were resolved by a senior retinal specialist. A predefined set of phenotypic characteristics was graded on MMI, including OCT, color fundus photography, fundus fluorescein angiography, and indocyanine green angiography.</div></div><div><h3>Main Outcome Measures</h3><div>Patients with polypoidal choroidal vasculopathy were distributed among 4 phenotypically different types, based on a previously published description: PCV with drusenoid age-related macular degeneration (AMD): PCV-AMD (type A); PCV without drusen but with a branching neovascular network (BNN): PCV-BNN (type B); isolated polypoidal choroidal vasculopathy (PCV-i) without drusen or a BNN: PCV-i (type C); and PCV with a background of central serous chorioretinopathy (CSC): PCV-CSC (type D).</div></div><div><h3>Results</h3><div>We included 332 eyes of 305 patients with PCV, with 179 of 305 patients being female (58.7%). The average age at diagnosis was 73 years. The included eyes had the following types: PCV-AMD in 188 eyes (58.4%); PCV-BNN in 61 eyes (18.9%); PCV-i in 15 eyes (4.7%); and PCV-CSC in 58 eyes (18.0%). Patients with PCV-AMD were older and more often female than patients with PCV-CSC. The median best-corrected visual acuity of affected eyes was 0.30 logarithm of the minimum angle of resolution (interquartile range, 0.10–0.52), with a large range in each type. A median of 2 polypoidal lesions per eye was found (range, 1–12), with no significant differences between types. The choroidal thickness beneath the fovea and beneath polypoidal lesions was significantly higher in PCV-CSC than in PCV-AMD (both <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Polypoidal choroidal vasculopathy in White patients comprises a spectrum of different phenotypes: it may present with signs of drusenoid AMD, with a background of CSC, or without signs of either diseases. We found a different phenotype distribution when compared with published findings in Asian patients with PCV.</div></div><div><h3>Financial Disclosure(s)</h3><div>The authors have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 10","pages":"Pages 994-1004"},"PeriodicalIF":5.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypic Spectrum of Benign Lobular Inner Nuclear Layer Proliferations","authors":"Michael Javaheri MD ,&nbsp;Christian J. Sanfilippo MD ,&nbsp;Sundeep K. Kasi MD ,&nbsp;Rachel Chen MD ,&nbsp;Jose M. Ruiz-Moreno MD ,&nbsp;Carol L. Shields MD ,&nbsp;David A. Saperstein MD ,&nbsp;Amy Yuan MD ,&nbsp;Brandon J. Lujan MD ,&nbsp;Heinrich Heimann MD ,&nbsp;Rutika Dodeja MBBS, DO ,&nbsp;Chris Bergstrom MD, OD ,&nbsp;Özge Yanık MD, MSc ,&nbsp;Jesse L. Berry MD ,&nbsp;Aaron Nagiel MD, PhD","doi":"10.1016/j.oret.2025.04.004","DOIUrl":"10.1016/j.oret.2025.04.004","url":null,"abstract":"<div><h3>Objective</h3><div>To report the clinical and imaging features of 8 new and 9 published cases with benign lobular inner nuclear layer proliferations (BLIPs).</div></div><div><h3>Design</h3><div>Retrospective case series and literature review.</div></div><div><h3>Participants</h3><div>Eight previously unreported patients from 7 institutions internationally and 10 reported cases in the literature.</div></div><div><h3>Methods</h3><div>Retrospective analysis of clinical and imaging features of BLIPs including systematic review of published cases using relevant terms.</div></div><div><h3>Main Outcomes and Measures</h3><div>Description of multimodal imaging and systemic findings in 17 patients with BLIPs.</div></div><div><h3>Results</h3><div>Eight new cases and 10 previously published cases with BLIPs were reviewed for clinical features, systemic associations, and imaging findings. The tumors were mostly unilateral (16 of 18 cases; 88%), associated with ipsilateral grouped congenital hypertrophy of the retinal pigment epithelium<span> lesions (16 of 20 eyes; 80%), and located posterior to the equator. In all eyes, the tumors were multifocal, and many had curvilinear extensions that extended beyond the central tumor lobules. OCT<span> demonstrated these lesions to be centered within the inner nuclear layer at the border of the inner plexiform layer<span> with no invasion of adjacent layers. Visual acuity was normal (mean: 0.024 logarithm of the minimum angle of resolution; range: −0.01 to 0.3) in all cases, and most patients were asymptomatic. No plausible genetic or systemic associations could be identified.</span></span></span></div></div><div><h3>Conclusions</h3><div>This expanded series of BLIPs further refines the clinical characteristics and imaging findings associated with this newly described benign retinal tumor.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 10","pages":"Pages 1017-1022"},"PeriodicalIF":5.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Center-Involved Diabetic Macular Edema With Visual Impairment Using Multimodal Artificial Intelligence Algorithms","authors":"Tien-En Tan MBBS (Hons), FRCOphth ,&nbsp;Yi Pin Ng BSc ,&nbsp;Claire Calhoun MS ,&nbsp;Jia Quan Chaung MBBS, FRCOphth ,&nbsp;Jie Yao MD ,&nbsp;Yan Wang PhD ,&nbsp;Liangli Zhen PhD ,&nbsp;Xinxing Xu PhD ,&nbsp;Yong Liu PhD ,&nbsp;Rick S.M. Goh PhD ,&nbsp;Gabriele Piccoli MSc, OD ,&nbsp;Stela Vujosevic MD, PhD ,&nbsp;Gavin S.W. Tan MBBS, PhD ,&nbsp;Jennifer K. Sun MD, MPH ,&nbsp;Daniel S.W. Ting MD, PhD","doi":"10.1016/j.oret.2025.04.016","DOIUrl":"10.1016/j.oret.2025.04.016","url":null,"abstract":"<div><h3>Purpose</h3><div>To develop artificial intelligence (AI) models for automated detection of center-involved diabetic macular edema (CI-DME) with visual impairment using color fundus photographs (CFPs) and OCT scans.</div></div><div><h3>Design</h3><div>Artificial intelligence effort using pooled data from multicenter studies.</div></div><div><h3>Participants</h3><div>Data sets consisted of diabetic participants with or without CI-DME, who had CFP, OCT, and best-corrected visual acuity (BCVA) obtained after manifest refraction. The development data set was from DRCR Retina Network clinical trials, external testing data set 1 was from the Singapore National Eye Centre, Singapore, and external testing data set 2 was from the Eye Clinic, IRCCS MultiMedica, Milan, Italy.</div></div><div><h3>Methods</h3><div>Artificial intelligence models were trained to detect CI-DME, visual impairment (BCVA 20/32 or worse), and CI-DME with visual impairment, using CFPs alone, OCTs alone, and both CFPs and OCTs together (multimodal). Data from 1007 eyes were used to train and validate the algorithms, and data from 448 eyes were used for testing.</div></div><div><h3>Main Outcome Measures</h3><div>Area under the receiver operating characteristic curve (AUC) values.</div></div><div><h3>Results</h3><div>In the primary testing set, the CFP model, OCT model, and multimodal model had AUCs of 0.848 (95% confidence interval [CI], 0.787–0.900), 0.913 (95% CI, 0.870–0.947), and 0.939 (95% CI, 0.906–0.964), respectively, for detection of CI-DME with visual impairment. In external testing data set 1, the CFP, OCT, and multimodal models had AUCs of 0.756 (95% CI, 0.624–0.870), 0.949 (95% CI, 0.889–0.989), and 0.917 (95% CI, 0.837–0.979), respectively, for detection of CI-DME with visual impairment. In external testing data set 2, the CFP, OCT, and multimodal models had AUCs of 0.881 (95% CI, 0.822–0.940), 0.828 (95% CI, 0.749–0.905), and 0.907 (95% CI, 0.852–0.952), respectively, for detection of CI-DME with visual impairment.</div></div><div><h3>Conclusions</h3><div>The AI models showed good diagnostic performance for the detection of CI-DME with visual impairment. The multimodal (CFP and OCT) model did not offer additional benefit over the OCT model alone. If validated in prospective studies, these AI models could potentially help to improve the triage and detection of patients who require prompt treatment.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 10","pages":"Pages 955-963"},"PeriodicalIF":5.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous Reduplications in Aggressive Retinopathy of Prematurity","authors":"Shakha MD,&nbsp;Parijat Chandra MD, DNB","doi":"10.1016/j.oret.2025.02.020","DOIUrl":"10.1016/j.oret.2025.02.020","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 10","pages":"Page e98"},"PeriodicalIF":5.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Progression of Pachychoroid Macular Atrophy in Central Serous Chorioretinopathy","authors":"Nasiq Hasan MD ,&nbsp;Arman Zarnegar MD ,&nbsp;Ninan Jacob MS ,&nbsp;Niroj Sahoo MS ,&nbsp;Stanley Saju DO ,&nbsp;Avery Zhou MD ,&nbsp;Charles C. Wykoff MD, PhD ,&nbsp;Halit Winter MD ,&nbsp;Manjot Gill MD ,&nbsp;Rufino Silva MD, PhD ,&nbsp;Pedro Pereira MD ,&nbsp;Felicia Hertkorn MD ,&nbsp;Lorenzo Ferro Desideri MD ,&nbsp;Marion R. Munk MD, PhD ,&nbsp;Carol Villafuerte-Trisolini MD ,&nbsp;Glenn Yiu MD, PhD ,&nbsp;Lihteh Wu MD ,&nbsp;Jay Chhablani MD","doi":"10.1016/j.oret.2025.04.005","DOIUrl":"10.1016/j.oret.2025.04.005","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;&lt;span&gt;Macular atrophy (MA) is a late-stage complication often associated with age-related macular degeneration (AMD). However, it can also occur in pachychoroid diseases, including &lt;/span&gt;central serous chorioretinopathy (CSCR), called pachychoroid MA (pMA). This study aimed to investigate the characteristics and progression of pMA in CSCR.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Design&lt;/h3&gt;&lt;div&gt;Multicenter retrospective study as part of the Macula Society International CSCR Research Network (MICRoN).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Participants&lt;/h3&gt;&lt;div&gt;Thirty-eight eyes of 32 patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;&lt;span&gt;Demographic and imaging data were collected. OCT and fundus autofluorescence images were analyzed to identify pMA features, including complete &lt;/span&gt;retinal pigment epithelium and outer retinal atrophy, pachychoroid phenotype, and baseline CSCR characteristics. The study comprised 2 parts: (1) progression analysis, comparing time to pMA among OCT features in cases without baseline pMA; and (2) follow-up analysis, including patients with at least a 12-month interval between 2 visits showing pMA progression. Pachychoroid macular atrophy area, number, and location were manually measured using the HEYEX-2 platform and ImageJ.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Main Outcome Measures&lt;/h3&gt;&lt;div&gt;Progression analysis: OCT features that contributed to faster development of pMA. Follow-up analysis: progression rate of pMA after square root transformation (SQRT) and features that contribute to faster progression in lesion size.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Among 1675 eyes with CSCR, the prevalence of pMA was 2.27% and the incidence of pMA was 0.89%. Eyes with intraretinal fluid (IRF) experienced faster time to development of pMA (31.34 ± 16.66 months) compared with those without IRF (64.13 ± 37.14 months, &lt;em&gt;P&lt;/em&gt; = 0.039). The mean pMA area increased from 1.65 ± 2.09 mm&lt;sup&gt;2&lt;/sup&gt; to 3.08 ± 3.14 mm&lt;sup&gt;2&lt;/sup&gt;, with a mean progression rate of 0.29 ± 0.28 mm&lt;sup&gt;2&lt;/sup&gt;/year. Central pMA exhibited a faster progression rate than noncentral pMA (0.13 ± 0.078 mm&lt;sup&gt;2&lt;/sup&gt;/year vs. 0.052 ± 0.055 mm&lt;sup&gt;2&lt;/sup&gt;/year, &lt;em&gt;P&lt;/em&gt; = 0.011). Larger baseline pMA area was significantly associated with quicker progression (&lt;em&gt;r&lt;/em&gt; = 0.65, &lt;em&gt;P&lt;/em&gt; ≤ 0.001). However, after SQRT of pMA area, no significant association with baseline area was found. There was significant reduction of central macular thickness (195.72 ± 96.58 to 153.64 ± 100.25 microns, &lt;em&gt;P&lt;/em&gt; = 0.034) and subfoveal choroidal thickness (372.92 ± 83.84 to 342.8 ± 78.33 microns, &lt;em&gt;P&lt;/em&gt; value = 0.029) at follow-up.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;&lt;span&gt;Pachychoroid MA in CSCR exhibits distinct characteristics compared with AMD-related geographic atrophy from established literature. It progresses at a slower rate, and larger lesions tend to advance more rapidly. Additionally, central pMA progresses faster than noncentral pMA. The presence of IRF during the &lt;/span&gt;disease c","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 10","pages":"Pages 984-993"},"PeriodicalIF":5.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pachyvitelliform Maculopathy","authors":"Maria Vittoria Cicinelli MD ,&nbsp;Lorenzo Bianco MD ,&nbsp;Prithvi Ramtohul MD ,&nbsp;Lorenzo Caminada MD ,&nbsp;Chiara Giuffré MD ,&nbsp;Maria Pia De Carlo MDs ,&nbsp;Matteo Oliari MSc ,&nbsp;Ugo Introini MD ,&nbsp;Francesco Bandello MD","doi":"10.1016/j.oret.2025.04.003","DOIUrl":"10.1016/j.oret.2025.04.003","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the prevalence, clinical features, associated factors, and natural history of pachyvitelliform maculopathy (PVM) within the pachychoroid disease spectrum (PDS).</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Subjects</h3><div>Patients affected with PDS were evaluated at a single retina referral center between 2006 and 2024.</div></div><div><h3>Methods</h3><div><span>Demographics, medical history, and imaging features were reviewed. Pachyvitelliform maculopathy was diagnosed based on the presence of acquired vitelliform lesions (AVLs), identified as hyperreflective material above the </span>retinal pigment epithelium<span> (RPE) band on spectral-domain OCT<span> and corresponding hyperautofluorescence on fundus autofluorescence imaging. Acquired vitelliform lesions were tracked longitudinally using serial OCT.</span></span></div></div><div><h3>Main Outcome Measures</h3><div>Factors associated with AVL development were assessed using multivariable logistic regression<span>. The hazard of AVL persistence was evaluated with Cox regression<span>. Complication rates were reported as absolute prevalence, and visual acuity (VA) changes were analyzed longitudinally using repeated measures modeling.</span></span></div></div><div><h3>Results</h3><div>Among 986 eyes with PDS, 48 (5%) demonstrated PVM. Key associations included recurrent fluid episodes (odds ratio [OR], 2.87; <em>P</em><span> = 0.002), thinner outer nuclear layer (OR, 0.89; </span><em>P</em> = 0.03), and choroidal folds (OR, 3.39; <em>P</em><span> = 0.002). Subfoveal AVLs were most common, observed in 79% of cases. Acquired vitelliform lesion typically developed at the apex of the subfoveal serous cavity or along its lateral edges, beginning with ellipsoid zone thickening, followed by suspended hyperreflective material settling onto the RPE and forming deposits. These deposits consolidated over time, appearing as “pachydrusen” or resembling the “double-layer sign.” Indocyanine green angiography highlighted localized choroidal vascular hyperpermeability at AVL sites. Subfoveal lesions, a thicker Haller's layer, and increased peripapillary choroidal thickness were associated with reduced AVL resolution (all </span><em>P</em> &lt; 0.05). Lesion turnover was slow (median 50 months); complications, including neovascularization (6%) and atrophy (4%), were rare, and VA remained stable over 7 years (<em>P</em> = 0.07).</div></div><div><h3>Conclusions</h3><div>Pachyvitelliform maculopathy represents a distinct phenotype within PDS, characterized by prolonged lesion persistence, recurrent fluid, and a relatively benign visual prognosis. Structural choroidal changes and RPE dysfunction drive lesion formation and progression.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 10","pages":"Pages 972-983"},"PeriodicalIF":5.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-Time Adverse Events in Pediatric Fluorescein Angiography: IV versus Oral","authors":"Osama Sorour MD ,&nbsp;Naira Ikram BS ,&nbsp;Scott Shuldiner MD ,&nbsp;Samet Gulkas MD ,&nbsp;Francisco Altamirano MD ,&nbsp;Ryan S. Meshkin MD ,&nbsp;Celine Chaaya MD ,&nbsp;Amanda Rich RN ,&nbsp;Efren Gonzalez MD ,&nbsp;Nimesh A. Patel MD","doi":"10.1016/j.oret.2025.04.020","DOIUrl":"10.1016/j.oret.2025.04.020","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 10","pages":"Pages 1027-1029"},"PeriodicalIF":5.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benign Lobular Inner Nuclear Layer Proliferations","authors":"Ozgur Yalcinbayir MD ,&nbsp;Gamze Ucan Gunduz MD ,&nbsp;Deniz Yalcinbayir MS","doi":"10.1016/j.oret.2025.02.011","DOIUrl":"10.1016/j.oret.2025.02.011","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 10","pages":"Page e94"},"PeriodicalIF":5.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}